Novavax Launches Midstage Coronavirus Vaccine Trial

Vaccine specialist Novavax (NASDAQ:NVAX) announced the launch of a phase 2b clinical trial in South Africa to test the effectiveness of its coronavirus vaccine, NVX-CoV2373. The trial is an opportunity for the company to test the vaccine in an environment where the pandemic is surging during the cold weather of winter. South Africa has had more than half the COVID-19 cases on the African continent.